Drug-device combinations in rare diseases: Challenges and opportunities

Area of Science:

• Pharmacology and Medical Device Technology
• Regulatory Science
• Rare Disease Therapeutics

Background:

• Drug-device combinations (DDCs) integrate pharmaceuticals with medical devices for enhanced therapeutic outcomes.
• Rare diseases affect millions globally, presenting unique challenges in treatment efficacy and safety.
• Current regulatory pathways for DDCs lack specific incentives for rare disease applications, unlike orphan drugs.

Purpose of the Study:

• To review regulatory approaches and case studies of DDCs in rare diseases.
• To identify specific challenges and opportunities in the development and approval of DDCs for rare diseases.
• To propose recommendations for tailored policies and incentives to advance DDCs in rare disease treatment.

Main Methods:

• Literature review of regulatory frameworks governing DDCs.
• Analysis of case studies involving DDCs for rare diseases.
• Examination of existing policies and incentives for orphan drugs and DDCs.

Main Results:

• The regulatory landscape for DDCs is complex and not optimized for rare diseases.
• Significant potential exists for DDCs to improve treatment for rare conditions through targeted delivery and reduced side effects.
• Lack of specific incentives and regulatory clarity presents a barrier to DDC development in rare diseases.

Conclusions:

• Tailored regulatory policies and financial incentives are crucial to unlock the potential of DDCs for rare diseases.
• Addressing current challenges can accelerate the development and accessibility of innovative DDC therapies for rare conditions.
• Further research and collaboration are needed to establish effective pathways for DDCs in rare disease therapeutics.